Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

321. Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature

Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature Dolan G, Smith L A, Collins S, Plumb J M CRD summary (...) This review assessed whether oral anticoagulation control differed for monitoring under different settings. The authors concluded that significant differences in International Normalised Ratio (INR) control were associated with different settings. Given a number of shortcomings in the review process, the authors' conclusions should be interpreted with caution. Authors' objectives To assess whether oral anticoagulation (OAC) control differed with respect to monitoring intensity and patient setting

DARE.2008

322. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis

Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C CRD summary This review found (...) that the risks of haemorrhage and thromboembolism were minimised at an international normalised ratio of two to three; moderately higher ratios appeared to be safe and more effective than lower ones. Significant heterogeneity and possible missed studies mean that the reliability of the authors' conclusions is unclear. Authors' objectives To evaluate the effects of anticoagulation intensity on the risks of haemorrhage and thromboembolism. Searching MEDLINE, EMBASE, Cochrane Central Register of Controlled

DARE.2008

323. Oral anticoagulants and non-cardioembolic stroke prevention

Oral anticoagulants and non-cardioembolic stroke prevention Oral anticoagulants and non-cardioembolic stroke prevention Oral anticoagulants and non-cardioembolic stroke prevention Schachter ME, Tran HA, Anand SS CRD summary This review concluded that oral anticoagulation should not be used for secondary prevention of stroke in patients who suffered a prior transient ischaemic attack or stroke of non-cardioembolic origin. This conclusion appeared to follow from the evidence presented (...) , but limitations in reporting made it difficult to establish the reliability of these conclusions. Authors' objectives To determine the efficacy and safety of oral anticoagulation in the secondary prevention of non-cardioembolic ischaemic transient ischaemic attack (TIA) and stroke. Searching MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL) databases were searched from 1960 to 2005 for relevant published evidence. Search terms were reported. Reference lists of retrieved studies

DARE.2008

324. Review: low-molecular-weight heparin prevented recurrent VTE more than oral anticoagulants in patients with cancer

Review: low-molecular-weight heparin prevented recurrent VTE more than oral anticoagulants in patients with cancer Review: low-molecular-weight heparin prevented recurrent VTE more than oral anticoagulants in patients with cancer | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: low-molecular-weight heparin prevented recurrent VTE more than oral anticoagulants in patients with cancer Article Text Treatment Review: low-molecular-weight heparin prevented recurrent VTE more than oral anticoagulants

Evidence-Based Nursing (Requires free registration)2008

325. Risk of fatal pulmonary embolism was 0.49 per 100 person-years after discontinuing anticoagulant therapy for venous thromboembolism

Risk of fatal pulmonary embolism was 0.49 per 100 person-years after discontinuing anticoagulant therapy for venous thromboembolism Risk of fatal pulmonary embolism was 0.49 per 100 person-years after discontinuing anticoagulant therapy for venous thromboembolism | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Risk of fatal pulmonary embolism was 0.49 per 100 person-years after discontinuing anticoagulant therapy for venous thromboembolism Article Text Prognosis Risk of fatal pulmonary embolism was 0.49 per 100 person-years after discontinuing

Evidence-Based Medicine (Requires free registration)2008

326. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W)

Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W) 18323500 2008 04 29 2008 05 29 2016 11 24 1524-4628 39 5 2008 May Stroke Stroke Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation (...) clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). 1482-6 10.1161/STROKEAHA.107.500199 In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation. However, because OAC carries important bleeding complications, risk stratification schemes have been devised to identify patients for whom the absolute benefits of OAC exceed its risks. Participants were risk-stratified

EvidenceUpdates2008

327. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism.

The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. BACKGROUND: The long-term risk for fatal pulmonary embolism (PE) after treatment of venous thromboembolism (VTE) may be an important factor in the decision to discontinue this treatment. OBJECTIVE: To provide reliable and precise estimates of the annual risk for fatal PE and the case-fatality rate of disease recurrence and to assess these outcomes according to the initial presentation (...) of VTE (deep venous thrombosis [DVT], PE, or both) and its etiology (secondary or idiopathic) in patients who have discontinued anticoagulant therapy. DESIGN: Prospective cohort study. SETTING: Academic medical centers. PATIENTS: Inception cohort of patients with a first episode of symptomatic VTE who discontinued anticoagulant therapy. MEASUREMENTS: Incidence rates of any fatal PE (which included sudden death from possible fatal PE) and definite or probable PE per 100 person-years of follow-up

Annals of Internal Medicine2007

328. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling

Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found

NIHR HTA programme2007

329. Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II.

Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II. AIMS: In mechanical heart valve recipients, low-dose international normalized ratio (INR) self-management of oral anticoagulants can reduce the risk of developing thrombo-embolic events and improve long-term survival compared with INR control by a general practitioner. Here, we present data on the safety of low-dose INR self-management. METHODS

EvidenceUpdates2007

331. Review: self monitoring increases the efficacy and safety of anticoagulant therapy

Review: self monitoring increases the efficacy and safety of anticoagulant therapy Review: self monitoring increases the efficacy and safety of anticoagulant therapy | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu (...) Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: self monitoring increases the efficacy and safety of anticoagulant therapy Article Text Therapeutics Review: self monitoring increases the efficacy and safety of anticoagulant therapy Free John Spandorfer , MD Statistics from Altmetric.com No Altmetric data available for this article. Heneghan C, Alonso-Coello P, Garcia-Alamino

Evidence-Based Medicine (Requires free registration)2007

332. What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve?

What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve? BestBets: What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve? What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve? Report By: Andrew Bayliss, Peter Faber, Joel (...) (caged-ball) valves Overall similar to the ACCP recommendations although no comments on combination with aspirin or dipyridamole Lowe et al, 1999 Scotland Scottish Intercollegiate Guidelines Guidelines based on available cohort & RCT's (Level Ib-IV) Need for anticoagulation therapy Patients with mechanical heart valves require long-term warfarin therapy (level IIa, IIb, III evidence) Varying levels of evidence Significant amount of evidence remains "expert opinion" Recommendations for first

BestBETS2007

333. WITHDRAWN: Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.

WITHDRAWN: Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. BACKGROUND: Atrial fibrillation (AF) carries a high risk of stroke and other thromboembolic events. Appropriate use of drugs to prevent thromboembolism in patients with AF involves comparing the patient's risk of stroke to the risk of hemorrhage from medication use. OBJECTIVES: To quantify risk of stroke, major hemorrhage and death from using medications that have been rigorously evaluated

Cochrane2007

334. WITHDRAWN: Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery.

WITHDRAWN: Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. BACKGROUND: The reported overall risk of deep venous thrombosis in gynaecological surgery ranges from 7 to 45%. Fatal pulmonary embolism is estimated to occur in nearly 1% of these women. Pharmaceutical interventions are one possible prophylactic measure for preventing emboli in women undergoing major gynaecological surgery. Agents include unfractionated heparin (low -dose (...) increase in injection site haematomas associated with heparin compared to placebo (OR 0.30, 95% CI 0.10 to 0.89). AUTHORS' CONCLUSIONS: Women, undergoing major gynaecological surgery and without contraindications to anticoagulants should be offered thromboprophylaxis. Evidence suggests that UH and LMWH are equally as effective in preventing DVT and the one trial available suggests that warfarin is as effective as UH. There is no evidence as yet to suggest that warfarin, heparin or aspirin reduce

Cochrane2007

335. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks.

Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. BACKGROUND: Non-valvular atrial fibrillation (AF) carries an increased risk of stroke mediated by embolism of stasis-precipitated thrombi originating in the left atrial appendage. Both oral anticoagulants and antiplatelet agents have proven effective for stroke prevention in most patients at high risk for vascular events (...) , but primary stroke prevention in patients with non-valvular AF potentially merits separate consideration because of the suspected cardio-embolic mechanism of most strokes in AF patients. OBJECTIVES: To characterize the relative effect of long-term oral anticoagulant treatment compared with antiplatelet therapy on major vascular events in patients with non-valvular AF and no history of stroke or transient ischemic attack (TIA). SEARCH STRATEGY: We searched the Cochrane Stroke Group Trials Register (June

Cochrane2007

336. Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters.

Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters. BACKGROUND: Central venous catheter (CVC) placement increases the risk of thrombosis in cancer patients. Thrombosis often necessitates the removal of the CVC, resulting in treatment delays and thrombosis related morbidity and mortality. OBJECTIVES: To evaluate the efficacy and safety of anticoagulation in reducing venous thromboembolic (VTE) events in cancer patients with CVC. SEARCH STRATEGY (...) : A comprehensive search for studies of anticoagulation in cancer patients up to January 2006 was conducted in the following databases: The Cochrane Central Register of Controlled Trials ( CENTRAL), MEDLINE, EMBASE and ISI the Web of Science. SELECTION CRITERIA: Randomized controlled trials (RCTs) comparing unfractionated heparin (UFH), low molecular weight heparin (LMWH), vitamin K antagonists (VKA), fondaparinux or ximelagatran to no intervention or placebo in cancer patients with a CVC or comparing two

Cochrane2007

337. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation.

Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. BACKGROUND: Basic research and clinical studies have generated the hypothesis that anticoagulation may improve survival in patients with cancer through an antitumour effect in addition to the antithrombotic effect. OBJECTIVES: To evaluate the efficacy and safety of heparin (including unfractionated heparin (UFH) and low molecular weight heparin (LMWH)) and fondaparinux to (...) improve survival of patients with cancer. SEARCH STRATEGY: A comprehensive search for studies of anticoagulation in cancer patients including (1) A January 2007 electronic search of the following databases: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and ISI the Web of Science; (2) Hand search of the American Society of Clinical Oncology and of the American Society of Hematology; (3) Checking of references of included studies; and (4) Use of "related article" feature

Cochrane2007

338. Is short-term anticoagulation necessary after mitral valve repair?

Is short-term anticoagulation necessary after mitral valve repair? BestBets: Is short-term anticoagulation necessary after mitral valve repair? Is short-term anticoagulation necessary after mitral valve repair? Report By: Sanjay Asopa, Anish Patel - Specialist Registrars in Cardiothoracic Surgery Search checked by Joel Dunning - Cardiothoracic Registrar RCS Institution: Wessex Cardiothoracic Unit, Southampton General Hospital Date Submitted: 21st December 2006 Date Completed: 9th May 2007 Last (...) 1980 and 1986. All patients were placed on warfarin on the third post-operative day. Warfarin was discontinued at the end of 3 months and patients were switched to antiplatelet therapy. High risk patients with predisposing factors were continued on warfarin long term basis Retrospective cohort study (level 2b) Long-term thrombo-embolic rates following mitral valve reconstruction. Of the 125 survivors without re-operation, (73 of 125) 58.4 % were on an anticoagulant or antiplatelet therapy.(34

BestBETS2007

339. Review: long term anticoagulation reduces recurrent venous thromboembolism

Review: long term anticoagulation reduces recurrent venous thromboembolism Review: long term anticoagulation reduces recurrent venous thromboembolism | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: long term anticoagulation reduces recurrent venous thromboembolism Article Text Therapeutics Review: long term anticoagulation reduces recurrent venous thromboembolism Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any or all of this article please use the link below which will take

Evidence-Based Medicine (Requires free registration)2007